Navigation Links
Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease

Conference Call Begins Today at 11:00 a.m. Eastern Time

LONDON, April 24, 2007 /PRNewswire-FirstCall/ -- Amarin Corporation plc ("Amarin" or the "Company") today announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's disease (HD). The Company conducted two Phase III double-blind, placebo-controlled studies in which HD patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of Miraxion daily for six months. Study data showed no statistically significant difference in either study between Miraxion and placebo with regard to the primary and secondary endpoints.

These top-line findings are inconsistent with earlier clinical trial data that showed statistical significance in a subset of HD patients with a CAG repeat length of less than or equal to 44.

The primary endpoint of the trials was a change in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). TMS-4 has been shown to be a sensitive measure of movement disorder in patients with HD. In addition, secondary endpoints included cognition and Total Functional Capacity outcomes. Miraxion was found to be safe and well-tolerated by patients.

Commenting on today's announcement, Rick Stewart, Chief Executive Officer of Amarin, said, "We are extremely surprised and disappointed by these top-line results, and we are analyzing the data in order to better understand the full and complete data set and outcomes. We are particularly disappointed that, at this time, we are not in a position to bring any positive news to those patients who are suffering from this devastating disease and to the broader HD community."

"Despite this setback with Miraxion to treat HD, we remain committed to developing Amarin's substantial central nervous system (CNS) development pipeline." commented Mr. Stewart. "We continue to evaluate the potential of
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/3/2015)... 2015 OmniSeq, LLC today announced the ... OmniSeq SM Genomic Network.  Recently, OmniSeq officially ... and announced it was making available a suite ... approach to genomic diagnostics that provides actionable results ... a rapidly expanding, multidisciplinary cancer care center that ...
(Date:8/3/2015)... 3, 2015 According to ... Research "Global Market Study on Physiotherapy Equipment - ... Growth by 2022", the global physiotherapy equipment market is estimated ... of 2015 and is expected to grow at ... to account for US$23.7 Bn by 2022. ...
(Date:8/3/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research ... results for the three months ended June 30, 2015, ... upcoming milestones for its clinical development programs. ... for CytRx. Enrollment in our ongoing pivotal global Phase ... (STS) continues on track to be completed in the ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July 28 ... leads to one pound of weight loss may not be accurate. While this system may ... one pound of fat varies – based both on the individual and at what point ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B ... B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... that while an overwhelming number of Hispanics believe people can positively affect their ... percent of participants queried said making diet changes was important. Far fewer participants ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany approach ... – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in the ... mission is to develop technology for the sake of humanity – continues to ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... insulin has been found to suppress the expression in ... pathogenesis of Alzheimer,s disease, according to new clinical research ... March online in the Journal of Clinical Endocrinology ... powerful, new role to play in fighting Alzheimer,s disease. ...
... the Centers for Disease Control and Prevention (CDC) ... (HICPAC) outline steps to eliminate bloodstream infections in ... most deadly and costly healthcare-associated infections (HAIs). ... Intravascular Catheter-Related Infections" will be published in its ...
... parents get their information about vaccines from their children,s ... parents, friends and family members and even celebrities as ... of a national survey conducted by University of Michigan ... of information in regards to vaccines, as well as ...
... 1 (HealthDay News) -- Exercise is a good way for ... says an expert. "People who have arthritis are often ... but the condition will only get worse if people don,t ... Center for Fitness in Maywood, Ill., said in a news ...
... brand new technology that promises a range of applications ... reached another world first in its development. This milestone ... and Technology Facilities Council,s (STFC) Daresbury Laboratory in Cheshire. ... start up of the pioneering EMMA accelerator which is ...
... to quickly distinguish individuals with active tuberculosis (TB) from ... the preliminary results of the study will be confirmed ... could allow more effective strategies to control the spread ... performed by a group of scientists from the Catholic ...
Cached Medicine News:Health News:Insulin could be Alzheimer's therapy 2Health News:CDC issues updated bloodstream infection prevention guidelines 2Health News:CDC issues updated bloodstream infection prevention guidelines 3Health News:U-M experts: Parents trust doctors most when it comes to information about vaccine safety 2Health News:Exercise Is Key for People With Arthritis: Expert 2Health News:EMMA milestone beams its way to a world first 2Health News:EMMA milestone beams its way to a world first 3Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 2Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: